Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical remission (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical improvement (Mayo score) (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical improvement (Mayo score) (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes total adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Participant satisfaction · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Improvement in range of jaw movement · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Change in gingival recession (REC) · Adults (> 18 years) with a clinical diagnosis of periodontitis, receiving active (non-surgical anti-infective) treatment
It is very uncertain whether adjunctive antimicrobial photodynamic therapy (aPDT) applied after… changes change in gingival recession (REC) compared with subgingival instrumentation (SI) alone (hand or power-driven, or… (very low certainty).
2 findings from 1 review
Pocket closure · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
The review found no eligible studies for this question.
1 finding from 1 review
Difficulty in mouth opening (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower difficulty in mouth opening (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Difficulty in swallowing (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower difficulty in swallowing (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Attachment change · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
The review found no eligible studies for this question.
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Change in bleeding on probing (BOP) · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
Adjunctive antimicrobial photodynamic therapy (aPDT) applied after… led to higher change in bleeding on probing (BOP) compared with submucosal instrumentation (SI) alone, or SI plus placebo/sham aPDT; GRADE not reported.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether hydrocortisone plus hyaluronidase (intralesional) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review